Abstract
The elucidation of multiple potential targets in cancer cells andthe development of multiple target-based antineoplastic agentsprovide unique challenges in clinical trial design. Many of theseagents are predicted to have cytostatic as opposed to cytotoxiceffects and thus the traditional surrogate endpoint of radiologictumor shrinkage may be inadequate. The ethical and safety issuesof obtaining multiple tumor biopsies further complicate theassessment of appropriate target inhibition in patients. Wediscuss specific issues that need to be addressed duringpreclinical, phase I, II, and III testing of these agents. Wepropose clinical trial designs, including a randomizeddiscontinuation design during phase II evaluation, that may beparticularly useful for cytostatic antineoplastic agents.
Similar content being viewed by others
References
Yang W, Del-Villar K, Urano J, et al.: Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein famesyltransferase. J Cell Biochem Suppl 27: 12-19, 1997
Denis LJ, Verweij J: Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs 15: 175-185, 1997
Harris AL: Antiangiogenesis for cancer therapy. Lancet 349 (Suppl 2): SII13-5, 1997
Biggs JR, Kraff AS: Inhibitors of cyclin-dependent kinase and cancer. J Mol Med 73: 509-514, 1995
Ingber D, Fujita T, Kishimoto S, et al.: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348: 55-57, 1990
Sledge GW Jr, Qulali M, Goulet R, et al.: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87: 1546-1550, 1995
Kohn EC, Reed E, Sarosy G, et al.: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 56: 569-573, 1996
Davis KL, Thal LJ, Gamzu ER, et al.: A double blind, placebocontrolled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 327: 1306-1308, 1992
Holford NH, Peace KE: Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA 89: 11471-11475, 1992
Bensimon G, Lacomblez L, Meininger V: A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330: 585-591, 1994
Paulus HE, Egger MJ, Ward JR, et al.: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 33: 477-484, 1990
Porter DR, Capell HA: The ‘natural’ history of active rheumatoid arthritis over 36 months-an analysis of patients enrolled into trials of potential disease-modifying anti-rheumatic drugs, and treated with placebo. Br J Rheumatol 32: 463-466, 1993
Kirwan JR: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 333: 142-146, 1995
Ferraccioli GF, Della-Casa-Alberighi O, Marubini E, et al.: Is the control of disease progression within our grasp? Review of the GRISAR study. (Gruppo Reumatologi Italiani Studio Artrite Reumatoide). Br J Rheumatol 35 Suppl 2: 8-13, 1996
Ratain MJ, Mick R, Schilsky RL, et al.: Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 85: 1637-1643, 1993
Millar AW, Brown PD, Moore J, et al.: Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 45: 21-26, 1998
Mani S, Ratain MJ: New phase I trial methodology. Semin Oncol 24: 253-261, 1997
Paxton JW, Kim SN, Whitfield LR: Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, inmice, rats, rabbits, dogs, and humans. Cancer Res 50: 2692-2697, 1990
DeMario MD, Ratain MJ: Oral chemotherapy: rationale and future directions. J Clin Oncol 16: 2557-2567, 1998
Merry C, Barry MG, Mulcahy F, et al.: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11: F29-33, 1997
Keogh A, Spratt P, McCosker C, et al.: Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 333: 628-633, 1995
Floren LC, Bekersky I, Benet LZ, et al.: Tacrolimus oral bioavailability doubles with coadminstration of ketoconazole. Clin Pharmacol Ther 62: 41-49, 1997
Spiro TP, Gerson SL, Hoppel CL, et al.: O6-Benzylguanine totally depletes alkylguanine DNA alkyltransferase in tumor tissue: A phase I phannacokinetic/pharmacodynamic study. Proc Amer Soc Clin Oncol 17: 212a, 1998
Eisenhauer EA: Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. Am Oncol 9: 1047-1052, 1998
Von Hoff DD: There are no bad anticancer agents, only bad clinical trial designs-twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 4: 1079-1086, 1998
Nemunaitis J, Poole C, Primrose J, et al.: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4: 1101-1109, 1998
Lippman SM, Hong WK, Benner SE. The chemoprevention of cancer, in Greenwals P, Kramer BS, Weed DL (eds). Cancer Prevention and Control. New York, NY: Marcel Dekker, Inc, 1995, pp 329-352
Kopec JA, Abrahamowicz M, Esdaile JM: Randomized discontinuation trials: Utility and efficiency. J Clin Epidemiol 46: 959-971, 1993
Tannock IF, Osoba D, Stockier MR, Ernst DS, Neville AJ, Moore MJ, Annitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 6: 1756-1764, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stadler, W.M., Ratain, M.J. Development of Target-Based Antineoplastic Agents. Invest New Drugs 18, 7–16 (2000). https://doi.org/10.1023/A:1006371512390
Issue Date:
DOI: https://doi.org/10.1023/A:1006371512390